Pyxis Oncology, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Pyxis Oncology completed a private placement on July 2, 2026, receiving $50 million in upfront gross proceeds with up to $64 million additional from warrant exercise. Combined with existing cash of $34.5 million (as of June 30, 2026), this extends runway into Q2 2027. The company reported Q2 2026 net loss of $25.3 million ($0.40 per share on 83.4M shares outstanding); R&D expenses were $16.1M, G&A $9.9M. MICVO monotherapy and combination data updates expected Fall 2026 and Q4 2026.
Why this rating
Financing is ~78% of company market cap, materially extends runway and funds key trials. However, company remains pre-revenue clinical stage with substantial burn ($25M/quarter), so runway extension is necessary but not transformational.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.